cilengitide has been researched along with fibrinogen in 2 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (fibrinogen) | Trials (fibrinogen) | Recent Studies (post-2010) (fibrinogen) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 34,477 | 1,707 | 7,083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adan, J; Albericio, F; Fernández-Llamazares, AI; Mitjans, F; Spengler, J | 1 |
| Harder, S; Klinkhardt, U; Kuczka, K; Meyer dos Santos, S; Nelson, K; Picard-Willems, B | 1 |
2 other study(ies) available for cilengitide and fibrinogen
| Article | Year |
|---|---|
Tackling lipophilicity of peptide drugs: replacement of the backbone N-methyl group of cilengitide by N-oligoethylene glycol (N-OEG) chains.
Topics: Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Ethylene Glycols; Fibrinogen; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydrophobic and Hydrophilic Interactions; Integrins; Ligands; Molecular Conformation; Snake Venoms; Structure-Activity Relationship; Vitronectin | 2014 |
The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow.
Topics: Adenosine Diphosphate; Blood Platelets; Collagen; Endothelial Cells; Fibrinogen; Humans; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Snake Venoms | 2015 |